Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics (NASDAQ: LXEO) announced that CEO R. Nolan Townsend will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexeo Therapeutics (NASDAQ: LXEO) announced that CEO R. Nolan Townsend will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 7:30 AM PT in San Francisco.
The presentation will be webcast live on the company's investor website under the News & Events tab, and a replay will be posted on the website after the presentation.
Details
News Market Reaction – LXEO
On Dec 22, the day this news came out, LXEO closed 2.71% above the previous close.
Data tracked by StockTitan Argus for the Dec 22 session.
Key Figures
- Conference edition
- 44th
- Annual J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- Scheduled conference presentation
- Presentation time
- 7:30 AM PT
- J.P. Morgan conference session
Historical Context
-
Announcement of virtual KOL session at Global CVCT Forum focused on PKP2-ACM.
-
Q3 2025 results with LX2006 FDA interactions, positive interim data, and financing.
-
Closing of public offering and concurrent private placement totaling about $153.8M.
-
Pricing of public offering and pre-funded warrants to raise about $135M.
-
Announcement of proposed underwritten public offering and concurrent private placement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
genetic medicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 AM PT in San Francisco, California.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.